190 related articles for article (PubMed ID: 29632734)
1. Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4
Tsuruta M; Ueda S; Yew PY; Fukuda I; Yoshimura S; Kishi H; Hamana H; Hirayama M; Yatsuda J; Irie A; Senju S; Yuba E; Kamba T; Eto M; Nakayama H; Nishimura Y
Oncoimmunology; 2018; 7(4):e1415687. PubMed ID: 29632734
[TBL] [Abstract][Full Text] [Related]
2. Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Yoshimura S; Osawa R; Kuroda Y; Hirayama M; Irie A; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Int J Cancer; 2014 Jan; 134(2):352-66. PubMed ID: 24734272
[TBL] [Abstract][Full Text] [Related]
3. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
4. An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs.
Hirayama M; Tomita Y; Yuno A; Tsukamoto H; Senju S; Imamura Y; Sayem MA; Irie A; Yoshitake Y; Fukuma D; Shinohara M; Hamada A; Jono H; Yuba E; Kono K; Yoshida K; Tsunoda T; Nakayama H; Nishimura Y
Oncoimmunology; 2016 Jun; 5(6):e1123368. PubMed ID: 27471607
[TBL] [Abstract][Full Text] [Related]
5. Identification of glypican-3-derived long peptides activating both CD8
Sayem MA; Tomita Y; Yuno A; Hirayama M; Irie A; Tsukamoto H; Senju S; Yuba E; Yoshikawa T; Kono K; Nakatsura T; Nishimura Y
Oncoimmunology; 2016; 5(1):e1062209. PubMed ID: 26942076
[TBL] [Abstract][Full Text] [Related]
6. Establishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigens.
Yatsuda J; Irie A; Harada K; Michibata Y; Tsukamoto H; Senju S; Tomita Y; Yuno A; Hirayama M; Abu Sayem M; Takeda N; Shibuya I; Sogo S; Fujiki F; Sugiyama H; Eto M; Nishimura Y
PLoS One; 2013; 8(12):e84908. PubMed ID: 24386437
[TBL] [Abstract][Full Text] [Related]
7. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
Nishimura Y; Tomita Y; Yuno A; Yoshitake Y; Shinohara M
Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer.
Obara W; Hara I; Kato Y; Kato R; Inoue K; Sato F; Mimata H; Nakamura Y; Fujioka T
Cancer Immunol Immunother; 2018 Sep; 67(9):1371-1380. PubMed ID: 29971464
[TBL] [Abstract][Full Text] [Related]
10. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
[TBL] [Abstract][Full Text] [Related]
11. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder.
Obara W; Eto M; Mimata H; Kohri K; Mitsuhata N; Miura I; Shuin T; Miki T; Koie T; Fujimoto H; Minami K; Enomoto Y; Nasu T; Yoshida T; Fuse H; Hara I; Kawaguchi K; Arimura A; Fujioka T
Ann Oncol; 2017 Apr; 28(4):798-803. PubMed ID: 27998971
[TBL] [Abstract][Full Text] [Related]
13. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes.
Schroers R; Shen L; Rollins L; Rooney CM; Slawin K; Sonderstrup G; Huang XF; Chen SY
Clin Cancer Res; 2003 Oct; 9(13):4743-55. PubMed ID: 14581345
[TBL] [Abstract][Full Text] [Related]
14. Identification of immunogenic LY6K long peptide encompassing both CD4
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Imamura Y; Yatsuda J; Sayem MA; Irie A; Hamada A; Jono H; Yoshida K; Tsunoda T; Daigo Y; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Oncoimmunology; 2014; 3():e28100. PubMed ID: 25340007
[TBL] [Abstract][Full Text] [Related]
15. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
17. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells.
Tomita Y; Harao M; Senju S; Imai K; Hirata S; Irie A; Inoue M; Hayashida Y; Yoshimoto K; Shiraishi K; Mori T; Nomori H; Kohrogi H; Nishimura Y
Cancer Sci; 2011 Jan; 102(1):71-8. PubMed ID: 21087352
[TBL] [Abstract][Full Text] [Related]
18. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
[TBL] [Abstract][Full Text] [Related]
19. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.
Schroers R; Shen L; Rollins L; Xiao Z; Sonderstrup G; Slawin K; Huang XF; Chen SY
Clin Cancer Res; 2003 Aug; 9(9):3260-71. PubMed ID: 12960111
[TBL] [Abstract][Full Text] [Related]
20. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]